In the present work, these have been proven to effectively redirect RevCAR T-cells expressing either E5B9 or E7B6 to eradicate CD33 and CD123-expressing AML cell lines both in vitro and in vivo. This evidence concerns the gene CD33 and acute myeloid leukemia.